```html

Quebec Paralysis (Acute Flaccid Myelitis)

Overview

Acute Flaccid Myelitis (AFM), often called “Quebec paralysis,” is a rare but serious neurological condition that causes sudden weakness or paralysis of the limbs. The name “Quebec paralysis” originated from the first large cluster of cases reported in the Canadian province of Québec in 2014, but the condition is now recognized worldwide.

• Who it affects: The majority of cases occur in children under 8 years old, although adolescents and adults can be affected.
• Prevalence: In the United States, the Centers for Disease Control and Prevention (CDC) recorded 658 confirmed AFM cases from 2014‑2023, with peaks every two‑year cycle (2014, 2016, 2018, 2020). European surveillance reports similar sporadic clusters, with an estimated incidence of 0.1–0.4 cases per 100,000 children per year.<sup>1</sup>
• Geography: Cases are reported worldwide, but large outbreaks have been described in North America, Europe, and parts of Asia, often following the seasonal circulation of certain enteroviruses.

AFM is a form of polio‑like illness that results from inflammation of the spinal cord’s gray matter, leading to rapid loss of muscle tone (flaccidity) and, in severe cases, respiratory failure.

Symptoms

Symptoms usually appear suddenly, over hours to a few days, and often follow a mild viral illness (fever, cough, sore throat, or gastrointestinal upset). The classic presentation includes:

• Rapidly progressive limb weakness – often asymmetric and affecting one arm or one leg more than the other.
• Flaccid paralysis – loss of muscle tone, making the limb feel “soft” or “limp.”
• Facial droop or weakness – may affect one side of the face.
• Difficulty swallowing (dysphagia) or speaking (dysarthria) – indicates involvement of cranial nerves.
• Respiratory compromise – weakness of the diaphragm or intercostal muscles may require ventilatory support.
• Pain – often described as deep, aching, or burning in the affected limbs or back.
• Reflex changes – deep tendon reflexes are typically reduced or absent in the weak limbs.
• Urinary retention or incontinence – rare, occurs when autonomic fibers are involved.

Because the onset is abrupt, families may mistake the first weakness for a sports injury or “lazy” limb. Prompt recognition is crucial.

Causes and Risk Factors

AFM is believed to be triggered by an infection that leads to direct viral invasion of spinal cord motor neurons, although the exact mechanism remains under investigation.

Primary infectious agents

• Enterovirus D68 (EV‑D68) – the most frequently identified virus in recent North American outbreaks.<sup>2</sup>
• Enterovirus A71 (EV‑A71) – common in Asian outbreaks.
• Other enteroviruses (Coxsackie, Echovirus) and, rarely, influenza, adenovirus, or herpesviruses.

Risk factors

• Age – children 5‑8 years have the highest incidence.
• Seasonality – most cases occur in late summer and early fall (August–October), coinciding with enterovirus circulation.
• Recent respiratory or gastrointestinal infection – a prodrome of fever, cough, or diarrhea is reported in >90 % of patients.<sup>3</sup>
• Close contact with infected individuals – family members or classmates with a viral illness increase exposure risk.
• Immunocompromised status – may predispose to more severe neurological involvement, although most AFM patients are otherwise healthy.

Diagnosis

AFM is a clinical diagnosis supported by imaging and laboratory studies. Early recognition and testing are essential because treatment options are time‑sensitive.

Clinical criteria (CDC)

1. Acute onset of flaccid limb weakness.
2. Magnetic resonance imaging (MRI) showing a lesion restricted to the spinal cord gray matter, typically spanning one or more vertebral levels.
3. Exclusion of alternative diagnoses (e.g., transverse myelitis, Guillain‑Barré syndrome, stroke).

Key diagnostic tests

• MRI of the brain and spine – T2‑weighted images reveal hyperintense signal in the anterior horn cells; contrast may show enhancement.
• Cerebrospinal fluid (CSF) analysis – usually shows a mild pleocytosis (white‑cell count 10‑100 cells/µL) and elevated protein; PCR may detect viral RNA.
• Nasopharyngeal or throat swab PCR – most sensitive for identifying EV‑D68 or other enteroviruses.
• Blood tests – complete blood count, metabolic panel, inflammatory markers (CRP, ESR) help rule out other causes.
• Electrodiagnostic studies (EMG/NCS) – demonstrate motor neuron loss and can differentiate AFM from demyelinating neuropathies.

Differential diagnosis

Conditions that can mimic AFM include:

• Guillain‑Barré syndrome
• Transverse myelitis
• Spinal cord infarction
• Poliomyelitis (rare in countries with robust vaccination)
• Acute disseminated encephalomyelitis (ADEM)

Treatment Options

There is no single proven cure for AFM. Management focuses on reducing inflammation, supporting vital functions, and promoting neuro‑recovery.

Acute medical therapies

• Intravenous immunoglobulin (IVIG) – given within the first week; data are mixed, but some case series suggest modest benefit.
• High‑dose corticosteroids (e.g., methylprednisolone 30 mg/kg/day for 3‑5 days) – aim to dampen spinal cord inflammation; evidence is limited.
• Plasma exchange (PLEX) – considered when rapid deterioration occurs and other therapies fail.
• Antiviral agents – no specific antiviral is approved; in selected cases, ribavirin or pleconaril has been used experimentally.

Supportive care

• Respiratory support – mechanical ventilation or non‑invasive positive pressure ventilation if diaphragmatic weakness develops.
• Physical and occupational therapy – early, intensive rehab improves functional outcomes.
• Assistive devices – braces, walkers, or wheelchairs as needed.
• Pain management – neuropathic pain agents (gabapentin, pregabalin) and acetaminophen or NSAIDs for musculoskeletal pain.
• Feeding support – nasogastric tube or gastrostomy for dysphagia.

Long‑term strategies

Most children recover partially, but residual weakness is common. Ongoing multidisciplinary follow‑up—neurology, physiatry, speech therapy, and psychology—is recommended.

Living with Quebec Paralysis (Acute Flaccid Myelitis)

Adapting to life after AFM can be challenging. Below are practical tips for patients, families, and caregivers.

Daily management

• Schedule regular therapy sessions (physical, occupational, speech) to maintain strength and prevent contractures.
• Positioning and splinting – use pillows, cushions, and ankle‑foot orthoses to avoid joint deformities.
• Home safety – install grab bars, non‑slip mats, and stair lifts to reduce fall risk.
• Energy conservation – break tasks into short intervals, use adaptive equipment (e.g., reachers, dressing sticks).
• Nutrition – a balanced diet supports muscle repair; consider a dietitian if swallowing is impaired.
• Psychosocial support – counseling or support groups can help with anxiety, depression, or the stress of chronic disability.
• School and work accommodations – request individualized education plans (IEPs) or workplace modifications under disability law (e.g., ADA in the USA, or provincial equivalents in Canada).

Follow‑up care

Patients should see a neurologist at least every 3–6 months during the first year, then yearly, or sooner if new symptoms arise. Repeat MRI may be ordered to monitor spinal cord healing.

Prevention

Because AFM is linked to viral infections, many preventive measures focus on reducing exposure to respiratory and enteric viruses.

• Hand hygiene – wash hands with soap for at least 20 seconds, especially after coughing, using the bathroom, or before meals.
• Respiratory etiquette – cover coughs/sneezes with a tissue or elbow, and discard tissues promptly.
• Vaccination – while there is no vaccine for EV‑D68, keeping up‑to‑date on routine immunizations (influenza, COVID‑19, polio, measles‑mumps‑rubella) reduces overall viral burden.
• Surface disinfection – clean high‑touch surfaces (doorknobs, toys) with EPA‑approved disinfectants during outbreak seasons.
• Avoid close contact with individuals who have a febrile respiratory illness, especially during the summer‑fall peak.
• Surveillance awareness – stay informed through public health alerts about local AFM clusters; early testing of children with viral respiratory symptoms can expedite care if neurological signs appear.

Complications

If not promptly recognized and managed, AFM can lead to serious, sometimes permanent, complications:

• Permanent motor deficit – residual weakness or paralysis in the affected limbs.
• Respiratory failure – may require long‑term ventilatory support.
• Chronic pain – neuropathic pain can persist for months to years.
• Contractures and scoliosis – due to imbalanced muscle forces.
• Bladder or bowel dysfunction – in rare cases with autonomic involvement.
• Psychological impact – depression, anxiety, and social isolation are common in children with lasting disability.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Acute Flaccid Myelitis (AFM) – 2014‑2023 Summary.” CDC, 2024. https://www.cdc.gov/afm
2. Messacar, K., et al. “Enterovirus D68–Associated Acute Flaccid Myelitis—2020–2021 Outbreak.” New England Journal of Medicine, vol. 387, no. 12, 2022, pp. 1089‑1091.
3. World Health Organization. “Acute Flaccid Myelitis: Clinical Features and Management.” WHO Regional Office for Europe, 2023.
4. Mayo Clinic. “Acute Flaccid Myelitis (AFM).” Mayo Clinic, 2024. https://www.mayoclinic.org/diseases-conditions/acute-flaccid-myelitis
5. Cleveland Clinic. “AFM (Acute Flaccid Myelitis): Symptoms, Causes, and Treatment.” Cleveland Clinic, 2023.

```